# A Study of NILK-2301 in Patients with Locally Advanced or Metastatic Low Tumor Volume (LTV) Colorectal Cancer

> **NCT06663839** · PHASE1 · RECRUITING · sponsor: **Light Chain Bioscience - Novimmune SA** · enrollment: 25 (estimated)

## Conditions studied

- Colorectal Cancer Metastatic

## Interventions

- **DRUG:** Biological NILK-2301

## Key facts

- **NCT ID:** NCT06663839
- **Lead sponsor:** Light Chain Bioscience - Novimmune SA
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-04-12
- **Primary completion:** 2025-10
- **Final completion:** 2026-01
- **Target enrollment:** 25 (ESTIMATED)
- **Last updated:** 2024-10-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06663839

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06663839, "A Study of NILK-2301 in Patients with Locally Advanced or Metastatic Low Tumor Volume (LTV) Colorectal Cancer". Retrieved via AI Analytics 2026-09-21 from https://api.ai-analytics.org/clinical/NCT06663839. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*